MedPath

Dexamethasone as an Immediate Intervention

Phase 1
Withdrawn
Conditions
Trauma
Interventions
Registration Number
NCT02753166
Lead Sponsor
NYU Langone Health
Brief Summary

To determine if a single dose of dexamethasone (5 mg) administered in the first 12 hours following a potentially traumatic event alters a) cortisol and FKBP5 RNA the next day in the periphery measured in saliva; b) FKBP5 methylation by 1 month; c) executive functioning and emotion regulation functioning; d) psychophysiological (heart rate, respiration, skin conductance) in response cued reminders of the trauma; e) enhances the likelihood of remission of PTSD symptom severity.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Adults 18-70 years
  • Evidence of acute Post Traumatic Event (PTE) exposure defined by Diagnostic and Statistical Manual criterion 'A'
  • Evidence of a significant stress response defined by DSM V PTSD criterion 'B' and meeting at least criteria for 'partial PTSD' or a minimum of 3 of 4 DSM V PTSD symptom criterion
  • Score of 60 or higher on the Subjective Units of Distress Scale (SUDS)
  • Living in New York tri-state area
  • Fluency in English, Spanish
Read More
Exclusion Criteria
  • Admission to an intensive care unit or other overnight admission
  • In the Emergency Department for more than 6 hours
  • Evidence of ongoing traumatic exposure (e.g. domestic violence)
  • Evidence of psychotic symptoms
  • Evidence of homicidality/suicidality
  • Adults with an open head injury, a positive CT scan, loss of consciousness >30 seconds or survivors in a coma
  • Adults in police custody or Department of Correction (DOC) patients
  • Inability to understand the study's procedures, risks, or side effects, or otherwise unable to give informed consent.
  • Females who are nursing or pregnant (as confirmed by a positive urine pregnancy test).
  • Permanent cardiac pacer implant.
  • . Self-reported medical conditions that may be affected by DEX including asthma, epilepsy,diabetes, liver disease, kidney disease, thyroid disorder, muscle disorder, history of malaria,tuberculosis, osteoporosis, glaucoma or cataracts.
  • Self-reported adverse reactions to steroids
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
DexamethasoneDexamethasone-
Primary Outcome Measures
NameTimeMethod
Change in score on PTSD symptom severity measured with the PTSD Check-List 5 (PCL-5)1 month, 3 months, 6 months, 9 months, and 12 months

Mean symptom severity on the PCL-5 will be compared between groups using an independent samples T-test.

Secondary Outcome Measures
NameTimeMethod
Cortisol Levels measured from saliva samples24 hours post ED departure
Score on Center for Epidemiologic Studies Depression Scale (CES-D)1 month, 3 months, 6 months, 9 months, and 12 months
Score on Perceived Ability to Cope with Trauma Scale (PACT)1 month, 3 months, 6 months, 9 months, and 12 months
Score on Subjective Units of Distress (SUDS)1 month, 3 months, 6 months, 9 months, and 12 months

Scale of 0 to 10 for measuring the subjective intensity of disturbance or distress currently experienced by an individual. The individual self assesses where they are on the scale.

Score on the Kessler 6 Scale1 month, 3 months, 6 months, 9 months, and 12 months

Measure of Psychological distress in the anxiety-depression spectrum

Score on Life Satisfaction Scale1 month, 3 months, 6 months, 9 months, and 12 months

The Satisfaction with Life Scale to assess satisfaction with people's lives as a whole. The scale does not assess satisfaction with specific life domains, such as health or finances, but allows subjects to integrate and weigh these domains in whatever way they choose.

Trial Locations

Locations (1)

New York University Medical Center

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath